Only
3% of the developmental pipeline is currently in the late stages of development,
with only one drug candidate in Pre-registration and two in Phase III. This
therefore limits the number of drugs with the potential to be approved during
the forecast period and subsequently the potential for market growth. Over two
thirds of the pipeline molecules (67%) are in the discovery or Pre-registration
Phases of development, suggesting a recent surge in interest in anti-obesity
drugs. This may be a reflection of the continued increase in the prevalence of
obesity and a need for additional treatment to the currently favored option of
lifestyle modification, through dieting and increased exercise.
The Growth of the Anti-obesity Drugs Market is Restricted by High Attrition
Rates
The successful transition of anti-obesity drugs from Phase I to market is very
difficult. The development of more than 80% of products is terminated before
reaching Pre-registration. This may contribute to the low number of drug
candidates seen at the later stages of the developmental pipeline. Furthermore,
previously approved drugs, including Sanofi-Aventis’ Acomplia (rimonabant) and
Knoll Pharmaceutical’s/Abbott Laboratories’ Meridia (sibutramine), were
withdrawn from the market in 2008 and 2010 respectively due to the emergence of
serious side effects post-marketing, such as severe depression, anxiety,
suicidal thoughts, and cardiovascular complications, including heart failure.
This has resulted in a stagnant anti-obesity market over the past decade, with
only orlistat being proven safe as a long-term treatment for obesity.
Recently Approved Product Expected to Drive Obesity Market
The global prevalence of obesity and overweight (anti-obesity medication is
also indicated for patients who are overweight with comorbidities) is very
high, with a minimum of 20% of the population falling into this category in the
countries covered in this report (US, UK, France, Germany, Italy, Spain and
Japan), rising to a maximum of 45%. Despite this, a very small percentage of
patients known to healthcare professionals to be obese are treated with
pharmacotherapy. This may be a result of several factors, such as the limited
efficacy of currently available drugs and the general unfavorable opinion of
healthcare professionals and patients of anti-obesity drugs due to side effects
and multiple withdrawals following negative post-marketing safety studies.
The current market, which is dominated by off-patent orlistat products, is
expected to grow at a modest Compound Annual Growth Rate (CAGR) of 20.7% from
approximately $750m in 2012 to approximately $2.6 billion in 2019. This growth
is mostly attributed to the performance of the recently approved Qsymia, which
is superior in terms of efficacy to the current best option for the long-term
treatment of obesity, namely orlistat, and to any of the late-stage pipeline
drugs. It is currently undergoing post-marketing studies to determine its
long-term cardiovascular safety.
To read more details please visit http://marketinforesearch.com/obesity-c-5_339_784/obesity-therapeutics-to-2019-safety-concerns-hinder-drug-performance-despite-large-market-opportunity-p-19983.html
or write us at CustomerCare@MarketInfoResearch.com
About us:
MarketInfoResearch.com (MIR) is an innovative platform for online market research reports & database. MIR offers a range of latest international publications from global industry and business analysis.
We provide a wide gamut of market research reports and database offerings such as business and industry analysis, global company profile, country reports etc. suited to serve your business needs.
No comments:
Post a Comment